Overcoming T-cell-mediated immunopathology to achieve safe respiratory syncytial virus vaccination

Future Virology

Volumn 3, Issue 5, 2008, Pages 445-454

  Castilow, Elaine M ^a   Varga, Steven M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Cytokine; Eosinophil; Lung; Mouse; T cell; Vaccine; Virus

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; EOTAXIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 12; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VACCINIA VIRUS VACCINE FUSION PROTEIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG RESPONSE; DRUG SAFETY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LOEFFLER PNEUMONIA; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SYSTEMIC DISEASE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS INFECTION; WEIGHT REDUCTION;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 55849152459     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.5.445     Document Type: Review

References (69)

1. Collins PL, Chanock RM: Fields Virology (4th Edition). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 1443-1485 (2001)
2. Simoes EA: Respiratory syncytial virus infection. Lancet 354, 847-852 (1999).
3. Johnson KM, Bloom HH, Mufson MA, Chanock RM: Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease. N. Engl. J. Med. 267, 68-72 (1962).
4. Hall CB, Walsh EE, Long CE, Schnabel KC: Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693-698 (1991).
5. Beem M: Repeated infections with respiratory syncytial virus. J. Immunol. 98, 1115-1122 (1967).
6. Ogra PL: Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr. Respir Rev. 5(Suppl. A), S119-S126 (2004).
7. Cunningham CK, McMillan JA, Gross SJ: Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 88, 527-532 (1991).
8. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA: Respiratory syncytial viral infection in infants with congenital heart disease. N. Engl. J. Med. 307, 397-400 (1982).
9. Altman CA, Englund JA, Demmler G et al.: Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr. Cardiol. 21, 433-438 (2000).
10. Meberg A, Bruu AL: Respiratory syncytial virus infections in congenital heart defects: hospitalizations and costs. Acta Paediatr.: 95, 404-406 (2006).
11. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE: Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759 (2005).
12. Hall CB, Powell KR, MacDonald NE et al.: Respiratory syncytial viral infection in children with compromised immune function. N Engl. J. Med. 315, 77-81 (1986).
13. Osterweil D, Norman D: An outbreak of an influenza-like illness in a nursing home. J. Am. Geriatr. Soc. 38, 659-662 (1990).
14. Agius G, Dindinaud G, Biggar RJ et al.: An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol. 30, 117-127 (1990).
15. Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O: The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr, Insfect. Dis. J.: 26, 733-739 (2007).
16. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89, 449-463 (1969).
17. Kim HW, Canchola JG, Brandt CD et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434 (1969).
18. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421 (1969).
19. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G: Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435-448 (1969).
20. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ: Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70, 2852-2860 (1996).
21. + T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. 78, 8753-8760 (2004).
22. Johnson TR, Teng MN, Collins PL, Graham BS: Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78, 6024-6032 (2004).
23. Johnson TR, Graham BS: Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73, 8485-8495 (1999).
24. Olson MR, Varga SM: CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol. 179. 5415-5424 (2007).
25. Nicholas JA, Rubino KL, Levely ME, Adams EG, Collins PL: Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64, 4232-4241 (1990).
26. Tang YW, Graham BS: Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T-lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Invest. 94, 1953-1958 (1994).
27. Johnson TR, Parker RA, Johnson JE, Graham BS: IL- 13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol. 170, 2037-2045 (2003).
28. Moghaddam A, Olszewska W, Wang B et al.: A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12, 905-907 (2006).
29. Melnick JL: Current status of poliovirus infections. Clin. Microbiol. Rev. 9, 293-300 (1996).
30. Werzberger A, Mensch B, Kuter B et al.: A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327, 453-457 (1992).
31. Innis BL, Snitbhan R, Kunasol P et al.: Protection against hepatitis A by an inactivated vaccine. JAMA 271, 1328-1334 (1994).
32. Srikiatkhachorn A, Braciale TJ: Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71, 678-685 (1997).
33. Openshaw PJ, Clarke SL, Record FM: Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4, 493-500 (1992).
34. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS: Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72, 2871-2880 (1998).
35. Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJ: Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J. Immunol. 161. 6215-6222 (1998).
36. Hancock GE, Tebbey PW, Scheuer CA, Pryharski KS, Heers KM, LaPierre NA: Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes. J. Med. Virol. 70, 301-308 (2003).
37. Srikiatkhachorn A, Chang W, Braciale TJ: Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol. 73, 6590-6597 (1999).
38. Pemberton RM, Cannon MJ, Openshaw PJ, Ball LA, Wertz GW, Askonas BA: Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J. Gen. Virol. 68(Pt 8), 2177-2182 (1987).
39. Bangham CR, Openshaw PJ, Ball LA, King AM, Wertz GW, Askonas BA: Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137, 3973-3977 (1986).
40. + T cell responses. J. Immunol. 165, 6487-6495 (2000).
41. + T cells. Immunity 15, 637-646 (2001).
42. Tebbey PW, Hagen M, Hancock GE: Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188, 1967-1972 (1998).
43. Walzl G, Matthews S, Kendall S et al.: Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J. Exp. Med. 193, 785-792 (2001).
44. Castilow EM, Meyerholz DK, Varga SM: IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 180, 2376-2384 (2008).
45. Hussell T, Khan U, Openshaw P: IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness. J. Immunol. 159, 328-334 (1997).
46. Openshaw PJ, Hussell T: The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus. Dev. Biol. Stand. 92, 179-185 (1998).
47. Andrew DP, Chang MS, McNinch J et al.: STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immunol. 161, 5027-5038 (1998).
48. Culley FJ, Pennycook AM, Tregoning JS, Hussell T, Openshaw PJ: Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J. Virol. 80, 4521-4527 (2006).
49. Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ: Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J. Virol. 79, 2050-2057 (2005).
50. Monick MM, Powers LS, Hassan I et al.: Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. J. Immunol. 179. 1648-1658 (2007).
51. Garvey TL, Dyer KD, Ellis JA et al.: Inflammatory responses to pneumovirus infection in IFN-α β-R gene-deleted mice. J. Immunol. 175, 4735-4744 (2005).
52. Castilow EM, Olson MR, Meyerholz DK, SM Varga: Differential role of γ-interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J. Virol. 82, 2196-2207 (2008).
53. Openshaw PJ, Pemberton RM, Ball LA, Wertz GW, Askonas BA: Helper T cell recognition of respiratory syncytial virus in mice. J. Gen. Virol. 69(Pt 2), 305-312 (1988).
54. + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. J. Immunol. 27, 3341-3349 (1997).
55. Sparer TE, Matthews S, Hussell T et al.: Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187, 1921-1926 (1998).
56. Hussell T, Pennycook A, Openshaw PJ: Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31, 2566-2573 (2001).
57. + cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 337, 335-343 (2005).
58. Openshaw PJ, Anderson K, Wertz GW, Askonas BA: The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J. Virol. 64, 1683-1689 (1990).
59. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186, 421-432 (1997).
60. + T cells during infection with respiratory syncytial virus are mediated by IFN-γ. Eur. J. Immunol. 32, 2117-2123 (2002).
61. Phipps S, Lam CE, Mahalingam S et al.: Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 110, 1578-1586 (2007).
62. Yamaguchi Y, Suda T, Suda J et al.: Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J. Exp. Med. 167, 43-56 (1988).
63. Yamaguchi Y, Hayashi Y, Sugama Y et al.: Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J. Exp. Med. 167, 1737-1742 (1988).
64. Horie S, Okubo Y, Hossain M et al.: Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern. Med. 36. 179-185 (1997).
65. Elazhary MA, Galina M, Roy RS, Fontaine M, Lamothe P: Experimental infection of calves with bovine respiratory syncytial virus (Quebec strain). Can. J. Comp. Med. 44, 390-395 (1980).
66. Gershwin LJ, Schelegle ES, Gunther RA et al.: A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16, 1225-1236 (1998).
67. Kalina WV, Woolums AR, Berghaus RD, Gershwin LJ: Formalin-inactivated bovine RSV vaccine enhances a Th2-mediated immune response in infected cattle. Vaccine 22, 1465-1474 (2004).
68. Antonis AF, van der Most RG, Suezer Y et al,: Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25, 4818-4827 (2007).
69. Boxus M, Tignon M, Roels S et al.: DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge. J. Virol. 81, 6879-6889 (2007).